Compare VanEck Gold Miners ETF (GDX) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Heron Therapeutics Inc — how do they compare? VanEck Gold Miners ETF trades at $88.6 (market cap $25.65B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: VanEck Gold Miners ETF is far larger — about 377.2× Heron Therapeutics Inc's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Heron Therapeutics Inc for 35 Days on average.
| GDX | HRTX | |
|---|---|---|
Market Cap | $25.65B | $68.01M |
Volume | 16,534,046 | 1,891,941 |
52-Week High | $115.84 | $1.49 |
52-Week Low | $68.28 | $0.27 |
Typical Hold Time | 76 Days | 35 Days |
Sector | — | Health |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $85.46, down 3.13% amid a bearish technical signal with 13 sell signals from moving averages. Recent news highlights pressure on gold miners from rising interest rates and silver's sharp decline, though some analysts see value in the sell-off. Key support lies at $84, with resistance at $86-87. The ETF offers exposure to gold mining equities but lacks disclosed fundamental ratios in this snapshot.
The outlook for GDX hinges on gold price direction and interest rate trends, with risks including metal volatility and macroeconomic headwinds. Opportunities exist if gold rebounds, but investor caution is warranted given technical weakness and mixed sentiment from institutional flows.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
